Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Research & Development (2021 - 2025)

PAVmed (PAVM) has 5 years of Research & Development data on record, last reported at $1.1 million in Q3 2025.

  • For Q3 2025, Research & Development changed N/A year-over-year to $1.1 million; the TTM value through Sep 2025 reached $3.5 million, changed N/A, while the annual FY2024 figure was $5.9 million, 58.45% down from the prior year.
  • Research & Development reached $1.1 million in Q3 2025 per PAVM's latest filing, up from $789000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $7.0 million in Q4 2021 and bottomed at $787000.0 in Q1 2025.
  • Average Research & Development over 5 years is $3.7 million, with a median of $3.5 million recorded in 2023.
  • Peak YoY movement for Research & Development: skyrocketed 78.94% in 2022, then tumbled 77.56% in 2024.
  • A 5-year view of Research & Development shows it stood at $7.0 million in 2021, then decreased by 4.23% to $6.7 million in 2022, then plummeted by 46.12% to $3.6 million in 2023, then crashed by 77.56% to $807000.0 in 2024, then soared by 34.82% to $1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $1.1 million in Q3 2025, $789000.0 in Q2 2025, and $787000.0 in Q1 2025.